Deprescription on oncological palliative care: an integrating review
Background: Patients on oncologic palliative care (OPC), due to diverse symptomatology and variable severity, tend to present polypharmacy that, although it seems justifiable in many cases, can pose health risks and negative consequences on patients’ quality of life. Thus, it is necessary to evaluate the presence of possible therapeutic futilities, guiding the process of deprescription, in which there is a reduction in the amount of medication after reviewing the treatment objectives and assessing risks and benefits. Aim: The objective of this study was to identify the main classes of drugs that are candidates for the deprescribing for OPC patients by reviewing the literatura of the last 8 years. Methods: The bibliographic search was performed in the Medline and LILACS databases. Inclusion criteria were articles published between 2010 and 2018, which dealt with the topic of deprescription in CPO. The publications were analyzed for Qualis and the level of scientific evidence, in order to identify the main drugs candidates for deprescription. Results: Twenty articles were evaluated, being only 4 randomized clinical trials (RCTs), with level II of scientific evidence. Among the classes of drugs that are candidates for deprescription, the following stand out: statins (20.37%) and antihypertensives (20.07%). ECRs that corroborate with scientific evidence of quality need to be developed for guidelines that make it possible to prescribe, especially for the population in CPO. Conclusion: We highlight the importance of the use of tools to identify inappropriate medicines, and the use of medication conciliation as a means of identifying them, as well as pharmacotherapeutic follow-up.
How to Cite
Copyright (c) 2019 RBFHSS and the Authors
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
The authors hereby transfer, assign, or otherwise convey to RBFHSS: (1) the right to grant permission to republish or reprint the stated material, in whole or in part, without a fee; (2) the right to print republish copies for free distribution or sale; and (3) the right to republish the stated material in any format (electronic or printed). In addition, the undersigned affirms that the article described above has not previously been published, in whole or part, is not subject to copyright or other rights except by the author(s), and has not been submitted for publication elsewhere, except as communicated in writing to RHFHSS with this document.
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC-BY-NC-ND) that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
This journal permits and encourages authors to post and archive the final pdf of the articles submitted to the journal on personal websites or institutional repositories after publication, while providing bibliographic details that credit its publication in this journal.